Tag: dna

Moderna’s COVID Shot Plasmid Contains Human Blood Gene Fragment Capable of Integrating Into DNA—Same System Dominating Post-Vaccine Injuries

Moderna’s COVID-19 vaccine plasmid contains a human α-globin DNA fragment regulating blood and cardiovascular biology, and because plasmids are integration-competent DNA molecules, this fragment is capable of inserting into the human genome—precisely as blood and cardiovascular injuries like myocarditis and pericarditis emerge as the dominant serious adverse events following Moderna vaccination.

In plain terms, Moderna’s shot carries a piece of human blood gene code that can lodge itself into patient DNA, raising the possibility that the very blueprint of the vaccine is fueling the same heart and blood injuries now seen at the top of its safety reports.

While most public discussion blames the spike protein or lipid nanoparticles for Moderna’s adverse events, the evidence here points to something no one is talking about—the plasmid blueprint itself may be driving the blood and heart injuries dominating the safety signal.

A September 2025 peer-reviewed paper in Molecular Therapy: Nucleic Acids confirms that Moderna’s mRNA-1273 (Spikevax) vaccine plasmid carries a 3’ untranslated region (UTR) from the human α-globin (HBA1) gene.

  • α-globin encodes part of hemoglobin, central to red blood cell stability and oxygen transport.
  • Its regulation is directly tied to blood and cardiovascular function—mutations cause α-thalassemia, anemia, and cardiac stress.
  • By design, Moderna’s blueprint hard-codes this human blood gene regulator into the plasmid template.

Keep reading

Giant, flightless bird is next target for de-extinction company Colossal Biosciences


A species of huge, flightless bird that once inhabited New Zealand disappeared around 600 years ago, shortly after human settlers first arrived on the country’s two main islands. Now, a Texas-based biotech company says it has a plan to bring it back.

Genetic engineering startup Colossal Biosciences has added the South Island giant moa — a powerful, long-necked species that stood 10 feet (3 meters) tall and may have kicked in self-defense — to a fast-expanding list of animals it wants to resurrect by genetically modifying their closest living relatives.

The company stirred widespread excitement, as well as controversy, when it announced the birth of what it described as three dire wolf pups in April. Colossal scientists said they had resurrected the canine predator last seen 10,000 years ago by using ancient DNA, cloning and gene-editing technology to alter the genetic make-up of the gray wolf, in a process the company calls de-extinction. Similar efforts to bring back the woolly mammoth, the dodo and the thylacine, better known as the Tasmanian tiger, are also underway.

To restore the moa, Colossal Biosciences announced Tuesday it would collaborate with New Zealand’s Ngāi Tahu Research Centre, an institution based at the University of Canterbury in Christchurch, New Zealand, that was founded to support the Ngāi Tahu, the main Māori tribe of the southern region of New Zealand.

The project would initially involve recovering and analyzing ancient DNA from nine moa species to understand how the giant moa (Dinornis robustus) differed from living and extinct relatives in order to decode its unique genetic makeup, according to a company statement.

“There is so much knowledge that will be unlocked and shared on the journey to bring back the iconic moa,” Ben Lamm, CEO and co-founder of Colossal Biosciences, said in the statement. For example, the company said, researching the genomes of all moa species would be “valuable for informing conservation efforts and understanding the role of climate change and human activity in biodiversity loss.”

Keep reading

Eight Healthy Babies Born via IVF using DNA from Three People

In the United Kingdom, medical professionals have successfully delivered eight babies using a pioneering fertility procedure that incorporates DNA from three individuals.

This method aims to safeguard children from inheriting severe mitochondrial disorders. The births represent a cautious advancement in assisted reproduction, prioritizing family health and stability.

The mothers involved carried mutations in their mitochondria, risking life-threatening conditions for their offspring. Mitochondria serve as cellular energy sources, essential for bodily functions. Without intervention, these defects could devastate future generations.

The United Kingdom amended its laws in 2015 to permit this technique, reflecting deliberate ethical review. In 2017, regulators issued the initial license to Newcastle University’s fertility clinic. This institution led the development over two decades.

Among the newborns are four boys and four boys, including identical twins, from seven women. All show no evidence of the anticipated mitochondrial ailments. One additional pregnancy continues under medical care.

Professor Doug Turnbull, a key researcher, described the results as reassuring for families and scientists alike. He highlighted the relief in achieving positive outcomes for patients.

Professor Mary Herbert, a senior team member, expressed fulfillment in seeing eight healthy infants. She noted the achievement rewards the extensive collaborative work.

Human genes primarily reside in the cell’s nucleus, totaling around 20,000. However, mitochondria add 37 genes of their own. Faulty mutations here can lead to profound cellular energy deficits.

Keep reading

Ancient ‘female-centered’ society thrived 9,000 years ago in Çatalhöyük

Ancient DNA from Stone Age burials in Turkey has finally put to rest a decades-long debate about whether the 9,000-year-old proto-city of Çatalhöyük was a matriarchal society. The research finally confirms what experts have long suspected: Women and girls were key figures in this agricultural society.

“With Çatalhöyük, we now have the oldest genetically-inferred social organisation pattern in food-producing societies,” study co-author Mehmet Somel, an evolutionary geneticist at Middle East Technical University in Turkey, told Live Science in an email. “Which turns out to be female-centered.”

The new research was published Thursday (June 26) in the journal Science.

Located in south-central Turkey, Çatalhöyük was built around 7100 B.C. and was occupied for nearly 1,000 years. The vast settlement — spread over 32.5 acres (13.2 hectares) — is known for its houses that were entered from the roofs, burials beneath the house floors, and elaborate symbolism that included vivid murals and a diverse array of female figurines.

When archaeologist James Mellaart first excavated Çatalhöyük in the early 1960s, he interpreted the numerous female figurines as evidence of a matriarchal society that practiced “mother goddess” worship, perhaps as a way of ensuring a good harvest following a major economic transition from foraging to cereal-based agriculture.

In the 1990s, Stanford archaeologist Ian Hodder took over excavations at Çatalhöyük, and his research suggested instead that the society was largely egalitarian, without meaningful social or economic differences between men and women.

To further investigate the social organization at Çatalhöyük, in a new study, a team of researchers that included both Somel and Hodder analyzed the DNA of 131 skeletons dated to between 7100 and 5800 B.C. that were buried beneath house floors.

The researchers connected 109 people across 31 buildings and found that all first-degree relatives (parents, children and siblings) were buried together in the same building, while second-degree (uncles, aunts, nephews, nieces and grandparents) and third-degree relatives (such as first cousins and great grandparents) were often buried in nearby buildings. This suggests that nuclear or extended families had a role in structuring Çatalhöyük households, the researchers wrote in the study.

Keep reading

Researchers Have Cracked the 4,500-Year-Old Genome of a Mummy From Egypt’s First Pyramid Age

An ancient Egyptian genome has finally been unraveled after four decades of study, thanks to a sample collected from a mummy dating back to the time of the first pyramids.

The achievement marks the first complete sequencing of a genome of such antiquity collected from the region. The genetic data revealed information about the movement of people over millennia, as 80% of the individual’s DNA corresponds to ancient North Africans, while 20% is related to ancient West Asians.

The remains reveal a story of a hard life of manual labor, lived by an individual who possibly belonged to an ancient Egyptian pottery community.

A Decades-Long Genetic Quest

Forty years ago, Svante Pääbo, a Nobel Prize-winning Swedish geneticist, conducted the first successful extraction of ancient Egyptian DNA, although his work only resulted in a partial sequence. Now, scientists at the Francis Crick Institute and Liverpool John Moores University (LJMU) have conducted the first complete sequencing after working with the oldest Egyptian DNA sample ever collected.

“Forty years have passed since the early pioneering attempts to retrieve DNA from mummies without successful sequencing of an ancient Egyptian genome,” said co-author Pontus Skoglund, Group Leader of the Ancient Genomics Laboratory at the Francis Crick Institute. “Ancient Egypt is a place of extraordinary written history and archaeology, but challenging DNA preservation has meant that no genomic record of ancestry in early Egypt has been available for comparison.” 

“Building on this past research, new and powerful genetic techniques have allowed us to cross these technical boundaries and rule out contaminating DNA, providing the first genetic evidence for potential movements of people in Egypt at this time,” Skoglund added.

Keep reading

NHS plans to DNA test all babies to assess disease risk

Every newborn baby in England will have their DNA mapped to assess their risk of hundreds of diseases, under NHS plans for the next 10 years.

The scheme, first reported by the Daily Telegraph, is part of a government drive towards predicting and preventing illness, which will also see £650m invested in DNA research for all patients by 2030.

Health Secretary Wes Streeting said gene technology would enable the health service to “leapfrog disease, so we’re in front of it rather than reacting to it”.

It comes after a study analysing the genetic code of up to 100,000 babies was announced in October.

The government’s 10-year plan for the NHS, which is set to be revealed over the coming few weeks, is aimed at easing pressure on services.

The Department for Health and Social Care said that genomics – the study of genes – and AI would be used to “revolutionise prevention” and provide faster diagnoses and an “early warning signal for disease”.

Screening newborn babies for rare diseases will involve sequencing their complete DNA using blood samples from their umbilical cord, taken shortly after birth.

There are approximately 7,000 single-gene disorders. The NHS study which began in October only looked for gene disorders that develop in early childhood and for which there are effective treatments.

Currently, newborn babies are offered a heelprick blood test that checks for nine serious conditions, including cystic fibrosis.

The health secretary said in a statement: “With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill-health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives.”

Streeting added: “The revolution in medical science means that we can transform the NHS over the coming decade, from a service which diagnoses and treats ill-health to one that predicts and prevents it.”

Sequencing DNA gives a lot of information about a person which can then be used to make predictions about the likelihood of them having particular genetic diseases, according to Prof Robin Lovell-Badge, a geneticist at the Francis Crick Institute.

These include conditions like muscular dystrophy, liver diseases and some kidney problems, he told BBC Radio 4’s Today programme.

Keep reading

FDA halts Biden-era program of sending Americans’ DNA to China for genetic engineering

The Trump administration is halting companies from conducting clinical trials in China using Americans’ DNA samples in a program authorized by the Biden administration, according to the Food and Drug Administration.

The FDA said an immediate review has begun on new clinical trials that involve sending living cells of U.S. citizens to China and other hostile states for “genetic engineering and subsequent infusion back into U.S. patients — sometimes without their knowledge or consent.”

The agency moved to halt the program based on what it said is mounting evidence that some of the trials were conducted without informing people involved that their biological material was being transferred and manipulated.

The activity “may have exposed Americans’ sensitive genetic data to misuse by foreign governments including adversaries,” the FDA said in a statement Wednesday.

FDA Commissioner Marty Makary said the unacknowledged transfer of DNA samples has raised questions about the integrity of U.S. biomedical research.

“We are taking action to protect patients, restore public trust and safeguard U.S. biomedical leadership,” Dr. Makary said. “The previous administration turned a blind eye and allowed American DNA to be sent abroad — often without the knowledge or understanding of trial participants,” he said.

The FDA said the suspect transfer of Americans’ biomedical samples was the result of a December 2024 policy by the Biden administration that was put in place by the Justice Department in April.

The Biden rule imposed export controls that limited the transfer of sensitive data to countries of concern. But the Biden administration specifically approved a “sweeping exemption” that allowed U.S. companies to send trial participants’ biological samples, including DNA, for processing overseas in FDA-regulated clinical trials.

Keep reading

‘Genetic optimization’: Embryo ranking treats children as marketable goods, critics warn

An embryo screening service is drawing sharp criticism from scientists, ethicists and faith leaders who say the technology turns parents into shoppers and children into products.

Manhattan biotech startup Nucleus Genomics is marketing its Nucleus Embryo platform as a tool for genetic “optimization.” It allows couples undergoing in vitro fertilization to upload and rank DNA from up to 20 embryos based on potential intelligence, anxiety, addiction risk and more.

Embryos can come from whichever egg and sperm sources were used in that cycle.

For a minimum of $5,999, parents can receive “polygenic risk scores” estimating the likelihood that their future children will develop diseases such as Alzheimer’s or diabetes or possess traits such as high IQ, low BMI, anxiety resistance or a particular eye color.

“Every parent wants to give their children more than they had,” Nucleus Genomics posted on X alongside a promotional video showing a dashboard where users can sort embryos by projected traits.

To some critics, however, the premise behind the tool is less about love and more about control.

“For some parents, it looks for things like the potential for diabetes, the potential for deafness, conditions that are treatable or healable with today’s modern medicine,” Emma Waters, policy analyst for the Center for Technology and the Human Person at The Heritage Foundation, told The Washington Times.

“But in many other cases, the ones that are equally if not more disturbing, parents are actively using this technology to select children that are the smartest, have a certain personality, are the right sex or otherwise fit their model image of what a child should be — whether that’s blue eyes or blond hair or something else,” Ms. Waters said.

Keep reading

The Weaponization of Gene-Edited Mosquitoes

There are several dimensions to the mosquito crisis. The release of gene-edited male mosquitoes, coupled with the development of a dengue and malaria vaccine

But that is but the tip of the iceberg.

According to F. William Engdahl in 2018, the weaponization of insects is on the drawing board of the Pentagon:

There is strong evidence that the Pentagon, through its research and development agency, DARPA, is developing genetically modified insects that would be capable of destroying agriculture crops of a potential enemy.

The claim has been denied by DARPA, but leading biologists have sounded the alarm on what is taking place using new “gene-editing” CRISPR technology to in effect weaponize insects.

It’s like a 21st Century update of the Biblical plague of locusts, only potentially far worse.

Under the DARPA project, Genetic Alteration Agents or viruses will be introduced into the insect population to directly influence the genetic makeup of crops.

DARPA plans to use leaf hoppers, white flies, and aphids to introduce select viruses into crops. Among other dubious claims they say it will help farmers combat ‘climate change’.

What no one can answer, especially as neither the Pentagon nor the US FDA are asking, is how will the genetically engineered viruses in the insects interact with other microorganisms in the environment?

If crops are constantly being inundated by genetically modified viruses, how could this could alter the genetics and immune systems of humans who depend on the crops?

See F. William Engdahl, Why Is the Pentagon “Weaponizing Insects”? October 30, 2018

This posting includes excerpts from Jordan Shachtel, Amie Wek and Jamie White followed by the article of F. William Engdahl.

The World Mosquito Program plans to release five billion mosquitoes into Brazil.

“And the hope is they will help save lives. [Once] you see the reductions in disease transmission, it doesn’t seem like a horror movie any more,” Scott O’Neill, director of the World Mosquito Program” (CBC, April 2023)

Implemented concurrently with the influx of 5 billion friendly mosquitoes, Brazil approved in March 2023 a vaccine against dengue.

Keep reading

Some Jolly Rancher sweets unsafe to eat, FSA says

A number of products from a brand of US sweets are “unsafe to eat” and contain ingredients which could damage DNA and increase the risk of cancer, the Food Standards Agency (FSA) has warned.

UK businesses and consumers are being urged to stop buying and selling the Jolly Ranchers products, owned by US company Hershey.

The FSA says they contain chemical compounds – mineral oil aromatic hydrocarbons (MOAH) and mineral oil saturated hydrocarbons (MOSH) – which are “not compliant with UK laws”.

The products pose a safety risk if consumed regularly over time but there is “no immediate cause for concern, as [the] food safety risk is low”, the agency adds.

In a food alert published on Wednesday evening, the FSA said: “MOAH can cause damage to DNA and has the potential to increase the risk of cancer, particularly if consumed in high quantities over a prolonged period of time.

“MOAH is a genotoxic carcinogen, therefore no exposure is without risk to human health.”

MOAH and MOSH are used in confectionery to prevent stickiness and create a glossy appearance.

According to the agency, The Hershey Company has been working with the UK government body to remove the affected Jolly Rancher products from the UK market since 2024, but some businesses in Britain have continued to import the products.

Keep reading